ProCE Banner Activity

Managing Elderly Patients With Advanced NSCLC

Clinical Thought
Should you use reduced intensity therapies for your elderly patients with advanced NSCLC? I discuss how to define “elderly” and my approach in caring for elderly patients with advanced NSCLC.

Released: January 30, 2017

Expiration: January 29, 2018

No longer available for credit.

Share

Faculty

Jared Weiss

Jared Weiss, MD

Assistant Professor of Medicine
Attending Physician

Department of Hematology and Oncology
University of North Carolina
Chapel Hill, North Carolina

Provided by

Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

AbbVie

Celgene

Genentech Roche Virology

Lilly

Merck Oncology

Novartis Pharmaceuticals Corporation

Faculty Disclosure

Primary Author

Jared Weiss, MD

Assistant Professor of Medicine
Attending Physician

Department of Hematology and Oncology
University of North Carolina
Chapel Hill, North Carolina

Jared Weiss, MD, has disclosed that he has received consulting fees from AstraZeneca, Biodesix, EMD Serono, Genentech, Lilly, and OncoPlex Diagnostics, and funds for research support from AstraZeneca/MedImmune, Astellas Pharma, Celgene, Merck, Novartis, and Pfizer.